Previously, nivolumab [an anti-programmed cell death 1 (PD-1) ICI] had been studied as monotherapy for patients with pretreated SCLC; however, it did not prove to be superior to the control (4). This evidence concerns the gene PDCD1 and small cell lung carcinoma.